指南与共识湿疹皮炎与荨麻疹

EADV瘙痒工作组慢性瘙痒与慢性痒疹白皮书

EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2024-05-13

EADV瘙痒工作组基于多次共识会议发布白皮书,聚焦慢性瘙痒(CP)与慢性痒疹(CPG)的疾病负担、诊疗现状与未来方向。文中指出CP在普通医学中常见、在皮肤科为最常见主诉,患病率随人口老龄化预计上升;CPG是CP谱系中最严重的疾病,与长期搔抓所致皮损及难治性瘙痒-搔抓循环相关。白皮书提出五项共识目标,呼吁提升疾病认知、优化诊疗框架并改善医疗可及性。

要点

  • CP在皮肤科为最常见主诉,患病率随人口老龄化预计上升。
  • CPG是CP谱系中最严重疾病,伴长期搔抓性皮损与难治性瘙痒-搔抓循环。
  • 白皮书提出五项共识目标,强调CP/CPG为慢性负担性疾病且多非传染性、非精神疾病所致。

核心结论

  • CP与CPG是慢性且负担沉重的疾病,可严重影响生活质量,需提升公众与卫生决策者认知并优化诊疗框架。
  • 目前获批疗法不足,且CP/CPG作为严重疾病的认知仍存在短板。

研究设计与样本

  • EADV瘙痒工作组基于多次共识会议决定发布本白皮书。

主要发现

  • CP在普通医学中常见,是普通皮肤科最常见的就诊主诉。
  • CP的临床表现、潜在病因与治疗策略异质,患者个体治疗目标及躯体、心理与经济负担也可能不同。
  • CPG与长期搔抓所致皮损及难治性瘙痒-搔抓循环相关。
  • CP与CPG在多数情况下为非传染性疾病,且并非由精神疾病引起。

关键数值与推荐

  • 共识目标包括:确保CP被视为严重疾病。
  • 共识目标包括:提升公众对CP与CPG作为慢性负担性疾病、可严重影响生活质量的认知与理解。
  • 共识目标包括:明确多数CP与CPG为非传染性且非精神疾病所致。
  • 共识目标包括:改善对CP患者的支持与治疗,帮助其管理疾病。
  • 共识目标包括:宣传现有疗法,包括现行指南。

临床怎么用

  • 面向卫生政策决策者、支付方与行政管理部门及实际照护环节,指出在医疗可及性与照护质量方面需改进之处。
  • 支持建立合理的临床框架以优化诊断与治疗。
  • 提升公众与卫生系统决策者对CP与CPG的疾病认知。

局限性

  • 原文未报告具体研究设计细节、样本量或定量数据。
  • 原文指出目前获批疗法仍不足,对CP/CPG作为严重疾病的理解仍有欠缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic pruritus (CP) is frequent in general medicine and the most common complaint in general dermatology. The prevalence of CP is expected to rise in the future due to the ageing population. The clinical presentation, underlying aetiology and treatment strategy of CP are heterogeneous. Also, individual treatment aims and physical, psychic and economic burdens of patients might vary. Chronic prurigo (CPG) is the most severe disease in the chronic pruritus spectrum, being associated with long-standing scratch-induced skin lesions and a therapy refractory itch-scratch-cycle. It is thus important to raise disease awareness for CP and CPG in the general public and among decision-makers in the health system. Further, there is a need to support a rational clinical framework to optimize both diagnostics and therapeutics. Currently, there is still a shortcoming regarding approved therapies and understanding CP/CPG as severe medical conditions. Therefore, the EADV Task Force Pruritus decided to publish this white paper based on several consensus meetings. The group consented on the following goals: (a) ensure that CP is recognized as a serious condition, (b) increase public awareness and understanding of CP and CPG as chronic and burdensome diseases that can greatly affect a person's quality of life, (c) clarify that in most cases CP and CPG are non-communicable and not caused by a psychiatric disease, (d) improve the support and treatment given to patients with CP to help them manage their disease and (e) publicize existing therapies including current guidelines. We aim to point to necessary improvements in access and quality of care directed to decision-makers in health policy, among payers and administrations as well as in practical care.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Ständer S, Pereira MP, Zeidler C, et al. EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions. J Eur Acad Dermatol Venereol. 2024. PMID: 38738586. doi:10.1111/jdv.20102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。